Introduction {#sec1}
============

Allergic rhinitis (AR) is a common nasal mucosal inflammation, approximately 10--20% of the global population suffers from AR, and the classic symptoms of AR are nasal congestion, nasal itching, sneezing, and rhinorrhea. Allergic conjunctivitis presents as itchy, watery eyes resulting from the same pathophysiology as AR and is not surprisingly a common comorbid condition.

As an allergen-mediated disorder of the nasal passage, AR shares several similarities with another allergic disease of the lower respiratory tract: asthma. Not surprisingly, the two conditions are often comorbid; 85% of patients with asthma have AR whereas 40% of patients suffering from AR have or will develop asthma \[[@B1]\]. As a type 1 immunoglobulin (Ig)E-mediated hypersensitivity process, symptoms of them are triggered by allergens. The reported prevalence of allergic diseases has been steadily increasing. The true incidence probably remains underestimated. Asthma, one of the most common chronic respiratory diseases of childhood, is characterized by recurrent respiratory symptoms, reversible variable airway obstruction, airway inflammation, and increased bronchial hyper-responsiveness \[[@B2]\]. Its incidence is on the rise among children, which brings heavy burden to the whole society and results in huge medical expenditure around the world. It is thought to be caused by a combination of genetic and environmental factors \[[@B5],[@B6]\].

AR and asthma are complex multifactorial disorders, with both genetic and environmental components determining disease expression, show strong familial aggregation and heritability \[[@B7],[@B8]\], thus suggesting that genetic risk factors may underlie the risk of developing, or the clinical presentation of, allergic diseases \[[@B9]\]. Allergic diseases are also associated with elevated serum IgE levels and increased mediator release from activated inflammatory cells. Allergens cross-link IgE bound to FcεRIα that causes FcεRI clustering and activates the receptor complexes (FcεRIα, FcεRIβ, and FcεRIγ-γ homodimer) on the surface of mast cells or basophils, releasing vasoactive mediators, such as histamine. Although the search for genetic susceptibility factors related to allergic diseases is a promising field, gene variations related to FcεRI as potential risk factors for allergic diseases have not been comprehensively analyzed, and the results available are in some cases contradictory, some studies showed the variant of Glu237Gly of FcεRIβ gene showed association with atopic diseases and the variant is also associated with very high total serum IgE levels \[[@B12]\], but others were showed no association with atopic asthma \[[@B20]\].

FcεRI has a tetrameric structure consisting of three distinct polypeptides including the IgE-binding α chain, 4-fold membrane-spanning β chain, and disulfide-linked γ--γ homodimer \[[@B23]\]. The β chain of the FcεRI is found on mast cells and basophils, and acts as a signal amplifier in mast cell activation \[[@B24]\]. Cross-linking of this receptor leads to increased IL-4 production by these cells. The aggregation of FcεRI by the bounding of IgE with multivalent antigens has been shown to induce the release of histamine, leukotrienes, and inflammatory cytokines, and plays an important role in allergic inflammation \[[@B27],[@B28]\]. Furthermore, the β chain was previously reported to amplify early activation signals 5--7-fold through FcεRI in humans \[[@B25]\]. The β chain has also been suggested to function as a stabilizer of the FcεRI complex \[[@B29]\]. It contains an immunoreceptor tyrosine-based activation motif, a conserved feature of many antigen receptors that imparts signaling competence. The FcεRI β chain acts as a signal amplifier through the immunoreceptor tyrosine-based activation motif in its C-terminal intracellular region. Mutations in the FCERIB gene could alter IL-4 production and thus modify IgE levels.

Several studies on the genetic background of atopy likely to contribute to the pathogenesis of allergies \[[@B30]\], of these, a significant role for polymorphisms in the FcεRI β chain in the manifestation of the phenotype has been suggested. Genetic linkage studies demonstrated that a locus in chromosome 11q13 \[[@B34]\] encompassing the β chain gene was linked to various allergic disorders and high levels of serum IgE \[[@B35]\]. Polymorphisms in FcεRIβ have been linked to atopy, asthma, and allergies. This meta-analysis comprehensively discussed the association between the FcεRIβ polymorphisms and allergic diseases risk.

Materials and methods {#sec2}
=====================

Strategy for literature search {#sec2-1}
------------------------------

The electronic databases of PubMed, Embase, Web of science, Chinese National Knowledge Infrastructure (CNKI), and WanFang database were comprehensively searched to retrieve relevant articles published between January 2000 and August 2017. Databases were searched using the search term: "bronchial asthma, asthma, allergic rhinitis, nasal allergy, allergic diseases", "Fc epsilon RI beta, FcεRIβ, high-affinity IgE receptor beta chain, beta-subunit of the high-affinity receptor for IgE", "single nucleotide polymorphism, SNP, polymorphism, polymorphisms" as well as their combinations were employed as the searching keywords. The corresponding Chinese version was used in the Chinese databases. To obtain more data, we manually searched the references of related articles. Our analysis only focused on the studies that were written in English and Chinese. When the same authors or laboratories reported this issue on the same population, only the latest published full-text article was included.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

The following criteria were set to choose the studies included in the current meta-analysis: (1) case--control design; (2) the study must offer the sample size, distribution of alleles, genotypes, or other information that can help us infer the results; and (3) the publication on the association between polymorphisms of FcεRIβ and risk of asthma and/or allergic rhinitis. The exclusion criterions were as follows: (1) review articles, case reports, and meta-analysis; (2) the studies were conducted on animals; (3) genotype distribution data were unavailable; and (4) when multiple publications reported on the same or overlapping data, we used the most recent or largest population.

Data extraction {#sec2-3}
---------------

Data were carefully extracted independently by two authors (Huan-huan Guo and Ping Luo) according to the inclusion and exclusion criteria. Disagreements were resolved through discussion and arbitration by a third author if necessary. For each study, the following data were recorded: first author, year of publication, country, age, allergic status, number of cases and controls, and genotype distributions in cases and controls.

Quality assessment {#sec2-4}
------------------

The quality of studies was independently assessed by the two reviewers using the Newcastle--Ottawa scale (NOS) \[[@B38]\] based on three aspects: selection, comparability, and exposure of cases and controls. NOS scores ranged from 0 to 9, and articles with a score equal to or higher than six were regarded as high quality.

Statistical analysis {#sec2-5}
--------------------

Hardy--Weinberg equilibrium (HWE) for the genotype distribution of FcεRIβ in controls was tested by *χ*^2^ analysis with exact probability. The pooled odd ratio (OR) with 95% confidence interval (CI) was used to assess the strength of the associations between the genetic variants and allergic diseases risk. For the FcεRIβ polymorphism, "A" stands for wild-type gene, and "B" for mutant gene, the allelic (B vs. A), heterozygous (AB vs. AA), homozygous (BB vs. AA), dominant (AB+BB vs. AA), and recessive (BB vs. AA+AB) genetic models were used to obtain pooled ORs. The evaluated genetic models for each study were based mostly on those used in primary studies. Heterogeneity assumption was evaluated by a *X*^2^ based *Q* test and *I^2^* test \[[@B39]\]. A significant *Q* test (*P*\<0.10) indicated heterogeneity across studies. *I^2^* was used to measure the percentage of variability in point estimated that due to heterogeneity rather than sampling error. When there was no statistical heterogeneity, we used a fixed effects model (the Mantel--Haenszel method) \[[@B40]\], otherwise, a random effects model (DerSimonian and Laird method) was used \[[@B41]\]. The subgroup analysis was performed according to ethnicity, allergic status, and HWE status of controls. Begg rank correlation method and the Egger linear regression method were used to assess potential publication bias \[[@B42],[@B43]\]. The meta-analysis was performed using STATA Version 12.0 (Stata Corp, College Station, TX, U.S.A.) software. *P* value less than 0.05 was considered statistically significant. All *P* values presented are two-tailed.

Results {#sec3}
=======

Main characteristics of the selected studies {#sec3-1}
--------------------------------------------

[Figure 1](#F1){ref-type="fig"} outlined the study process of selection. Briefly, we first identified 234 articles. After applying the inclusion and exclusion criteria, a total of 29 articles including 6496 allergic diseases patients and 5828 controls were screened out. Of the 29 articles, 9 were written in Chinese \[[@B22],[@B44]\] and 20 in English \[[@B13],[@B52]\]. Among them, 22 were conducted in Asian populations and 7 in Caucasian populations. The FcεRIβ polymorphism was measured by seven different methods (ARMS-PCR, PCR-SSCP, PCR-RFLP, SNP-IT™, ABI, MALDI-TOF, and TaqMan). Within the genotype distribution in the controls, the value of HWE was either extracted in the articles directly or calculated using the data of controls. Only three studies deviated from HWE \[[@B52],[@B60],[@B49]\]. [Table 1](#T1){ref-type="table"} listed the main characteristics of included studies. [Table 2](#T2){ref-type="table"} exhibited the distribution information of alleles and genotypes of FcεRIβ polymorphism.

![Flow chart of selection process in this meta-analysis](bsr-38-bsr20180177-g1){#F1}

###### Main characteristics of included studies in this meta-analysis

  First author                         Year   Country             Ethnicity   Allergic status                Sample size   Genotype distribution   Genotyping methods   *P* for HWE   Quality score                                                                           
  ------------------------------------ ------ ------------------- ----------- ------------------------------ ------------- ----------------------- -------------------- ------------- --------------- ------- -------- -------- -------- ------- ------- ----------- -------- ---
  Laprise, C. \[[@B14]\]               2000   France and Canada   Caucasian   Asthma                         100/100       80                      19                   1             179             21      98       2        0        198     2       ARMS-PCR    0.92     7
  Soriano, J.B. \[[@B52]\]             2000   Spain               Caucasian   Asthma                         146/50        134                     11                   1             280             12      43       4        3        93      7       ARMS-PCR    \<0.05   6
  Takabayashi, A, \[[@B20]\]           2000   Japan               Asian       Asthma                         100/100       69                      27                   4             166             34      65       33       2        162     38      PCR-SSCP    0.35     7
  Chen, H. \[[@B44]\]                  2000   China               Asian       Asthma                         101/60        59                      39                   3             157             45      30       16       1        76      18      PCR-RFLP    0.50     8
  Nagata, H. \[[@B15]\]                2001   Japan               Asian       Allergic rhinitis              233/100       155                     76                   7             373             93      77       18       5        172     28      PCR-RFLP    0.01     6
  Zeng, L.X. [@B45]\]                  2001   China               Asian       Asthma                         69/28         61                      5                    3             127             11      27       1        0        55      1       ARMS-PCR    0.92     8
  Cui, T.P. \[[@B17]\]                 2003   China               Asian       Asthma                         216/198       125                     80                   11            165             51      148      46       4        171     27      PCR-RFLP    0.85     8
  Tang, Y. \[[@B46]\]                  2003   China               Asian       Asthma                         60/65         49                      11                   0             109             11      61       4        0        126     4       ARMS-PCR    0.80     7
  Korzycka-Zaborowska, B. \[[@B21]\]   2004   Poland              Caucasian   Asthma and allergic rhinitis   98/87         92                      6                    0             190             6       83       4        0        170     4       ARMS-PCR    0.83     8
  Rigoli, L. \[[@B18]\]                2004   Italy               Caucasian   Asthma and allergic rhinitis   100/103       79                      16                   5             178             22      102      1        0        205     1       PCR-SSCP    0.96     7
  Zhang, X.Z. \[[@B53]\]               2004   China               Asian       Asthma                         141/157       81                      57                   3             219             63      108      42       7        258     56      ARMS-PCR    0.27     8
  Zhang, X.Z. \[[@B53]\]               2004   Malaysia            Asian       Asthma                         68/100        49                      19                   0             117             19      77       23       0        177     23      ARMS-PCR    0.19     8
  Zhang, X.Z. \[[@B53]\]               2004   India               Asian       Asthma                         82/98         71                      10                   1             152             12      80       18       0        178     18      ARMS-PCR    0.32     8
  Cui, T.P. \[[@B47]\]                 2004   China               Asian       Asthma                         106/106       60                      40                   6             160             52      78       26       2        182     30      PCR-RFLP    0.92     8
  Zhao, K.S. \[[@B49]\]                2004   China               Asian       Asthma                         151/105       126                     23                   2             275             27      92       13       0        197     13      ARMS-PCR    0.50     6
  Liu, T. \[[@B22]\]                   2006   China               Asian       Asthma                         60/50         45                      14                   1             48              11      39       10       1        88      12      PCR-RFLP    0.71     8
  Kim, E.S. \[[@B55]\]                 2009   Korea               Asian       Asthma                         347/127       244                     99                   4             582             112     99       28       0        224     30      SNP-IT™     0.16     7
  Wang, J.Y. \[[@B19]\]                2009   China               Asian       Asthma                         449/512       309                     121                  16            739             153     314      165      27       793     219     ABI         0.39     7
  Dmitrieva-Zdorova, E.V. \[[@B59]\]   2012   Russia              Caucasian   Asthma                         224/172       221                     3                    0             441             7       170      2        0        342     2       MALDI-TOF   0.94     7
  Zheng, B.Q. \[[@B51]\]               2012   China               Asian       Asthma                         198/110       126                     61                   11            313             83      76       29       5        181     39      PCR-RFLP    0.31     7
  Ramphul, K. \[[@B60]\]               2014   India               Asian       Asthma                         192/188       170                     21                   1             361             23      163      24       1        350     26      TaqMan      0.91     8
  Ramphul, K. \[[@B60]\]               2014   China               Asian       Asthma                         192/192       139                     45                   8             327             57      136      38       18       323     61      PCR-RFLP    \<0.05   7
  Amo, G. \[[@B61]\]                   2016   Spain               Caucasian   Allergic rhinitis              149/526       146                     3                    0             295             3       144      277      105      1013    39      TaqMan      0.18     7
  Amo, G. \[[@B61]\]                   2016   Spain               Caucasian   Asthma and allergic rhinitis   366/526       330                     33                   0             695             37      144      277      105      1013    39      TaqMan      0.18     7
  Hua, L. \[[@B62]\]                   2016   China               Asian       Asthma                         1000/1000     65                      276                  659           1594            406     23       289      688      1665    335     TaqMan      0.25     7
                                                                                                                                                                                                                                                                              
  **-109C/T**                                                                                                              **TT**                  **TC**               **CC**        **T**           **C**   **TT**   **TC**   **CC**   **T**   **C**                        
  Hizawa, N. \[[@B13]\]                2000   Japan               Asian       Asthma                         226/226       85                      123                  18            277             175     108      99       19       312     140     PCR-RFLP    0.58     8
  Cui, T.P. \[[@B17]\]                 2003   China               Asian       Asthma                         216/198       87                      106                  23            140             76      76       103      19       128     70      PCR-RFLP    0.06     8
  Cui, T.P. \[[@B47]\]                 2004   China               Asian       Astnma                         106/106       44                      52                   10            140             72      41       57       8        139     73      PCR-RFLP    0.05     7
  Gan, X. \[[@B48]\]                   2004   China               Asian       Asthma                         45/45         23                      12                   10            58              32      19       14       12       52      38      PCR-RFLP    0.02     7
  Zhao, K.S. \[[@B50]\]                2004   China               Asian       Asthma                         126/87        46                      69                   11            161             91      40       38       9        118     56      PCR-RFLP    0.995    8
  Hizawa, N. \[[@B54]\]                2006   Japan               Asian       Asthma                         374/374       157                     178                  39            485             263     156      169      49       483     265     TaqMan      0.76     8
  Kim, E.S. \[[@B55]\]                 2009   Korea               Asian       Asthma                         347/127       159                     167                  20            470             224     69       54       3        187     67      SNP-IT™     0.04     6
  Li, H. \[[@B56]\]                    2009   China               Asian       Asthma                         192/192       110                     58                   24            291             93      78       90       24       245     139     PCR-RFLP    0.04     7
  Sharma, S. \[[@B57]\]                2009   India               Asian       Asthma                         237/221       37                      113                  87            188             286     74       108      39       256     186     TaqMan      0.97     8
  Tikhonova, V. \[[@B58]\]             2010   Russia              Caucasian   Asthma                         140/136       53                      69                   18            175             105     48       70       18       167     105     PCR-RFLP    0.34     7
  Ramphul, K. \[[@B60]\]               2014   India               Asian       Asthma                         189/188       35                      99                   55            163             215     35       87       66       162     214     TaqMan      0.51     8
  Ramphul, K. \[[@B60]\]               2014   China               Asian       Asthma                         192/192       78                      90                   24            245             139     110      58       24       291     93      PCR-RFLP    \<0.05   7
  Amo, G. \[[@B61]\]                   2016   Spain               Caucasian   Allergic rhinitis              149/526       47                      67                   35            161             137     144      277      105      565     487     TaqMan      0.18     7
  Amo, G. \[[@B61]\]                   2016   Spain               Caucasian   Asthma and allergic rhinitis   366/526       100                     188                  78            388             344     144      277      105      565     487     TaqMan      0.18     7
  Hua, L. \[[@B62]\]                   2016   China               Asian       Asthma                         1000/1000     148                     436                  416           1268            732     124      470      406      1282    718     TaqMan      0.50     7
                                                                                                                                                                                                                                                                              
  **RsaI_in2**                                                                                                             **AA**                  **AB**               **BB**        **A**           **B**   **AA**   **AB**   **BB**   **A**   **B**                        
  Chen, H. \[[@B44]\]                  2000   China               Asian       Asthma                         101/60        9                       38                   54            56              146     1        17       42       19      101     PCR-RFLP    0.63     8
  Leung, T.F. \[[@B16]\]               2002   China               Asian       Asthma                         75/70         3                       22                   50            27              123     3        23       44       30      110     ARMS-PCR    0.998    8
  Korzycka-Zaborowska, B. \[[@B21]\]   2004   Poland              Caucasian   Asthma and allergic rhinitis   98/87         83                      15                   0             180             16      82       5        0        169     5       ARMS-PCR    0.78     8
                                                                                                                                                                                                                                                                              
  **RsaI_ex7**                                                                                                             **AA**                  **AB**               **BB**        **A**           **B**   **AA**   **AB**   **BB**   **A**   **B**                        
  Chen, H. \[[@B44]\]                  2000   China               Asian       Asthma                         101/60        93                      8                    0             194             8       53       6        0        112     6       PCR-RFLP    0.68     8
  Leung, T.F. \[[@B16]\]               2002   China               Asian       Asthma                         76/70         70                      6                    0             146             6       65       5        0        135     5       ARMS-PCR    0.76     8
                                                                                                                                                                                                                                                                              
  **I181L**                                                                                                                **II**                  **IL**               **LL**        **I**           **L**   **II**   **IL**   **LL**   **I**   **L**                        
  Soriano, J.B. \[[@B52]\]             2000   Spain               Caucasian   Asthma                         146/50        146                     0                    0             292             0       50       0        0        100     0       ARMS-PCR    1        7
  Zhao, K.S. \[[@B49]\]                2004   China               Asian       Asthma                         144/100       26                      117                  1             169             119     48       52       0        148     52      ARMS-PCR    \<0.05   6

Abbreviations: ARMS-PCR, primer amplification refractory mutation system polymerase chain reaction; HWE, Hardy--Weinberg equilibrium; MALDI-TOF, matrix-assisted laser desorption/ionization-time of flight mass spectrometry; NA, not available or applicable; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; PCR-SSCP, polymerase chain reaction-single strand conformation polymorphism; SNP, single nucleotide polymorphism.

Bold text indicates five different polymorphisms of FcεRIβ.

###### Summary ORs and 95% CIs of FcεRIβ polymorphisms and allergic diseases risk

  Variables                         *N*   B vs. A                 AB + BB vs. AA   BB vs. AA + AB   BB vs. AA               AB vs. AA                                                                                                                              
  --------------------------------- ----- ----------------------- ---------------- ---------------- ----------------------- ----------- ------- ----------------------- --------- ------ ---------------------- --------- ------ ----------------------- --------- ------
  Overall                           25    **1.28 (1.06, 1.53)**   \<0.001          63.1             1.00 (0.60, 1.67)       \<0.001     94.1    1.62 (0.85, 3.11)       \<0.001   80.2   0.79 (0.39, 1.60)      \<0.001   77.6   1.02 (0.63, 1.67)       \<0.001   93
  Ethnicity                                                                                                                                                                                                                                                        
  Caucasian                         7     1.80 (0.72, 4.53)       \<0.001          79               0.64 (0.08, 4.95)       \<0.001     96      0.40 (0.02, 6.79)       \<0.001   81     0.13 (0.00, 4.05)      \<0.001   86.8   0.72 (0.10, 5.10)       \<0.001   95.2
  Asian                             18    **1.23 (1.05, 1.45)**   0.004            53.6             1.19 (0.92, 1.54)       \<0.001     73.2    **2.10 (1.22, 3.62)**   \<0.001   68.8   0.96 (0.60, 1.55)      0.021     46.6   1.19 (0.92, 1.55)       \<0.001   71
  Allergic status                                                                                                                                                                                                                                                  
  Asthma                            20    **1.25 (1.04, 1.51)**   \<0.001          60.5             1.19 (0.91, 1.57)       \<0.001     73.7    **2.09 (1.19, 3.65)**   \<0.001   67.7   0.97 (0.58, 1.62)      0.011     49.4   1.21 (0.92, 1.58)       \<0.001   70.2
  Allergic rhinitis                 2     0.69 (0.12, 3.97)       0.006            86.9             0.12 (0.00, 55.88)      \<0.001     98.9    0.21 (0.00, 18.15)      0.003     88.6   0.06 (0.00, 57.66)     \<0.001   95.1   0.15 (0.00, 53.67)      \<0.001   98.8
  Allergic rhinitis and/or Asthma   3     2.74 (0.65, 11.43)      0.012            77.3             1.02 (0.02, 60.58)      \<0.001     97.3    0.55 (0.00, 1117.47)    \<0.001   93.1   0.17 (0.00, 1213.83)   \<0.001   94.9   1.02 (0.03, 37.61)      \<0.001   96.5
  HWE                                                                                                                                                                                                                                                              
  ≥0.05                             22    **1.33 (1.08, 1.63)**   \<0.001          65               1.01 (0.56, 1.81)       \<0.001     94.7    1.99 (0.98, 4.08)       \<0.001   78.2   0.93 (0.40, 2.20)      \<0.001   80.8   0.99 (0.57, 1.72)       \<0.001   93.6
  \<0.05                            3     1.03 (0.64, 1.66)       0.103            56               1.06 (0.58, 1.92)       0.06        64.5    0.77 (0.40, 1.48)       0.477     0      0.45 (0.23, 0.88)      0.360     2.2    1.41 (0.88, 2.26)       0.223     33.3
  **-109C/T**                                                                                                                                                                                                                                                      
  Overall                           15    1.10 (0.95, 1.28)       \<0.001          76.8             1.08 (0.88, 1.33)       0.06        73.8    **1.58 (1.26, 1.98)**   \<0.001   66.4   1.12 (0.87, 1.44)      0.001     62     1.06 (0.86, 1.31)       \<0.001   71.8
  Ethnicity                                                                                                                                                                                                                                                        
  Caucasian                         3     1.00 (0.87, 1.15)       0.922            0                0.92 (0.75, 1.15)       0.716       0       **1.50 (1.18, 1.92)**   0.866     0      1.03 (0.77, 1.37)      0.929     0      0.89 (0.71, 1.11)       0.59      0
  Asian                             12    1.13 (0.93, 1.36)       \<0.001          81.1             1.13 (0.88, 1.47)       \<0.001     78.4    **1.60 (1.19, 2.14)**   \<0.001   71.6   1.16 (0.83, 1.62)      \<0.001   69.9   1.12 (0.86, 1.46)       \<0.001   76.3
  Allergic status                                                                                                                                                                                                                                                  
  Asthma                            13    1.11 (0.93, 1.33)       \<0.001          79.7             1.11 (0.87, 1.42)       \<0.001     76.8%   **1.58 (1.20, 2.08)**   \<0.001   69.6   1.14 (0.83, 1.56)      \<0.001   67.4   1.10 (0.86, 1.41)       \<0.001   74.4
  Allergic rhinitis                 1     0.99 (0.76, 1.28)       --               --               0.82 (0.55, 1.21)       --          --      **1.65 (1.07, 2.55)**   --        --     1.02 (0.62, 1.69)      --        --     0.74 (0.49, 1.13)       --        --
  Allergic rhinitis and/or Asthma   1     1.03 (0.85, 1.24)       --               --               1.00 (0.74, 1.35)       --          --      **1.46 (1.05, 2.02)**   --        --     1.07 (0.73, 1.58)      --        --     0.98 (0.71, 1.34)       --        --
  HWE                                                                                                                                                                                                                                                              
  ≥0.05                             12    1.06 (0.91, 1.24)       \<0.001          76.8             1.02 (0.82, 1.27)       \<0.001     72.7    **1.54 (1.19, 1.99)**   \<0.001   72.2   1.08 (0.82, 1.44)      0.001     66.4   0.99 (0.80, 1.23)       \<0.001   68.8
  \<0.05                            3     1.30 (0.87, 1.94)       0.042            68.5             1.40 (0.88, 2.23)       0.084       59.7    **1.80 (1.10, 2.92)**   0.349     5.1    1.34 (0.69, 2.62)      0.212     35.4   1.45 (0.86, 2.43)       0.072     62
  **RsaI_in2**                                                                                                                                                                                                                                                     
  Overall                           3     1.14 (0.45, 2.88)       0.005            81.3             1.01 (0.21, 4.78)       0.049       66.7    0.84 (0.33, 2.17)       0.045     75     0.45 (0.06, 3.55)      0.119     58.8   1.13 (0.281, 4.54)      0.1       56.5
  **RsaI_ex7**                                                                                                                                                                                                                                                     
  Overall                           2     0.91 (0.41, 2.04)       0.659            0                0.90 (0.40, 2.07)       0.651       0       --                      --        --     --                     --        --     0.90(0.40, 2.07)        0.651     0
  **I181L**                                                                                                                                                                                                                                                        
  Overall                           2     **2.00 (1.35, 2.97)**   --               --               **4.19 (2.35, 7.47)**   --          --      3.11 (0.13, 76.84)      --        --     5.49 (0.22, 139.56)    --        --     **4.15 (2.33, 7.41)**   --        --

Bold values indicate statistically significant results.

Association of E237G and -109C/T polymorphisms in asthma and/or allergic rhinitis risk {#sec3-2}
--------------------------------------------------------------------------------------

Twenty-five case--control studies involving the E237G polymorphism with 10,084 individuals (5081 cases and 5003 controls) were included in this meta-analysis. The overall results suggested that the allelic model of E237G polymorphism had an increased the risk of the allergic diseases (B vs. A: OR = 1.28, 95% CI = 1.06--1.53, *P*\<0.001, *I^2^* = 63.1%, [Figure 2](#F2){ref-type="fig"}). No significant association was revealed in the pooled results under other genetic model statistically. For subgroup analysis based on the ethnicity, significantly increased risk were observed in Asian population for allelic model (B vs. A: OR = 1.23, 95% CI = 1.05--1.45, *P*=0.004, *I^2^* = 53.6%, [Figure 3](#F3){ref-type="fig"}) and recessive genetic model (BB vs. AA + AB: OR = 2.10, 95% CI = 1.22--3.62, *P*\<0.001, *I^2^* = 68.8%). In allergic status subgroup analysis, we also observed increased risk of asthma for allelic model (B vs. A: OR = 1.25, 95% CI = 1.04--1.51, *P*\<0.001, *I^2^* = 60.5%, [Figure 4](#F4){ref-type="fig"}) and recessive genetic model (BB vs. AA + AB: OR = 2.09, 95% CI = 1.19--3.65, *P*\<0.001, *I^2^* = 67.7%). For subgroup analysis based on source of controls and HWE status of controls, a significant association was found (B vs. A: HWE ≥ 0.05, OR = 1.33, 95% CI = 1.08--1.63, *P*\<0.001, *I^2^* = 65%, [Figure 5](#F5){ref-type="fig"}). [Table 2](#T2){ref-type="table"} presented the detailed results of the meta-analysis.

![ORs and 95% CIs for the associations between E237G polymorphism and allergic diseases risk in allelic genetic model for overall populations](bsr-38-bsr20180177-g2){#F2}

![ORs and 95% CIs for the associations between E237G polymorphism and allergic diseases risk in allelic genetic model by ethnicity](bsr-38-bsr20180177-g3){#F3}

![ORs and 95% CIs for the associations between E237G polymorphism and allergic diseases risk in allelic genetic model by allergic status](bsr-38-bsr20180177-g4){#F4}

![ORs and 95% CIs for the associations between E237G polymorphism and allergic diseases risk in allelic genetic model by HWE](bsr-38-bsr20180177-g5){#F5}

A total of 15 eligible studies, consisting of 3909 cases and 4145 controls focused on -109 C/T polymorphisms. The overall OR with its 95% CI revealed a significantly increased risk of allergic diseases in recessive genetic model (BB vs. AA + AB: OR = 1.58, 95% CI = 1.26--1.98, *P*\<0.001, *I^2^* = 66.4%). No significant association was revealed in the other genetic models. In recessive genetic model, significant increased risk was found in all the three subgroup analysis by ethnicity (BB vs. AA + AB: Caucasian, OR = 1.50, 95% CI = 1.18--1.92, *P*=0.866, *I^2^* = 0%; Asian, OR = 1.60, 95% CI = 1.19--2.14, *P*\<0.001, *I^2^* = 71.6%), allergic status (BB vs. AA + AB: asthma, OR = 1.58, 95% CI = 1.20--2.08, *P*\<0.001, *I^2^* = 69.6%; allergic rhinitis, OR = 1.65, 95% CI = 1.07--2.55; OR = 1.46, 95% CI = 1.05--2.02), and HWE (BB vs. AA + AB: HWE ≥ 0.05, OR = 1.54, 95% CI = 1.19--1.99, *P*\<0.001, *I^2^* = 72.2%; HWE \< 0.05, OR = 1.80, 95% CI = 1.10--2.92, *P*=0.349, *I^2^* = 5.1%) respectively.

[Table 3](#T3){ref-type="table"} summarized the association between the clinical characteristics and the polymorphisms of E237G and -109C/T, including the gender, age, positive RAST, and total serum IgE level.

###### Clinical characteristics of E237G and -109 C/T polymorphisms

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                Sex (F/M)   Age (years)   Positive RAST (≥0.35 UA/ml)   Total IgE                Case         Control                                                                                                      
  ------------------------------------ ----------- ------------- ----------------------------- ------------------------ ------------ ---------------- ---------------------------------- -------------------------------------------------------- --------------------------------------------------------
  E237G                                                                                                                                                                                                                                           

  Laprise, C. \[[@B14]\]               41/59       NA            27 ± 2 (18--35)               NA                       --           --               --                                 --                                                       --

  Soriano, J.B. \[[@B52]\]             92/54       NA            58 ±16 (23--93)               NA                       68           NA               Geometric mean total IgE in IU/l   72.4                                                     NA

  Takabayashi, A. \[[@B20]\]           42/44       58/56         --                            --                       --           --               IgE level (IU/ml)                  1080 ± 1381                                              34--10,430

  Nagata, H. \[[@B15]\]                --          --            7--71                         15--79                   --           --               IgE level (IU/ml)                  641.5 ± 1234                                             56.1 ± 59.2

  Zeng, L.X. \[[@B45]\]                32/37       12/16         14--63                        21--50                   --           --               IgE level (μg/l)                   611 ± 82.6                                               53 ± 7.1

  Cui, T.P. \[[@B17]\]                 101/115     93/105        19.6 ± 21.9 (3--65)           22.3 ± 23.6 (3--60)      --           --               IgE-log (IU/ml)                    GG 2.622 ± 0.937\                                        NA
                                                                                                                                                                                         EG 2.418 ± 0.894\                                        
                                                                                                                                                                                         2.306 ± 0.915                                            

  Tang, Y. \[[@B46]\]                  --          --            --                            --                       --           --               --                                 --                                                       --

  Korzycka-Zaborowska, B. \[[@B21]\]   --          --            18--45                        18--45                   --           --               --                                 --                                                       --

  Rigoli, L. \[[@B18]\]                58/42       50/53         Children 5--13\               Children 6--14\          --           --               IgE-log (IU/ml)                    Children EE 2.63 ± 0.56/EG 2.37 ± 0.56/GG 2.44 ± 0.56\   Children EE 1.73 ± 0.57/EG 1.73 ± 0.58/GG 1.75 ± 0.57\
                                                                 Relatives 29--48              Relatives 33--49                                                                          Relatives EE 2.98 ± 0.43/EG 2.76 ± 0.43/GG 2.54 ± 0.48   Relatives EE 1.67 ± 0.50/EG 1.65 ± 0.58/GG 1.64 ± 0.45

  Zhang, X.Z., China \[[@B53]\]        77/64       53/104        52 ± 16                       32 ± 9                   70           NA               IgE level (IU/ml)                  EE 247 ± 30\                                             NA
                                                                                                                                                                                         EG + GG 248 ± 30                                         

  Zhang, X.Z., Malaysia \[[@B53]\]     43/25       45/55         45 ± 14                       34 ± 9                   56.7         NA               IgE level (IU/ml)                  EE 375 ± 47\                                             NA
                                                                                                                                                                                         EG + GG 341 ± 60                                         

  Zhang, X.Z., India \[[@B53]\]        50/32       39/59         50 ± 17                       34 ± 10                  63           NA               IgE level (IU/ml)                  EE 367 ± 36\                                             NA
                                                                                                                                                                                         EG + GG 446 ± 65                                         

  Cui, T.P. \[[@B47]\]                 47/59       48/54         40.37 ± 15.09 (18--69)        37.12 ± 12.63 (20--60)   --           --               IgE-log (IU/ml)                    EE 2.3060 ± 0.9152\                                      NA
                                                                                                                                                                                         EG 2.4180 ± 0.8936\                                      
                                                                                                                                                                                         GG 2.7220 ± 0.9374                                       

  Zhao, K.S. \[[@B49]\]                60/91       42/63         1.5--14                       2--14                    EE 91\       EE 5 EG + GG 2   IgE-log (IU/ml)                    EE 2.33 ± 0.68\                                          EE 1.49 ± 0.07\
                                                                                                                        EG + GG 19                                                       EG + GG 2.43 ± 0.59                                      EG + GG 1.52 ± 0.09

  Liu, T. \[[@B22]\]                   --          --            36.5                          38.5                     EE 19\       EE 39\           --                                 --                                                       --
                                                                                                                        EG 9\        EG 10\                                                                                                       
                                                                                                                        GG 1         GG 1                                                                                                         

  Kim, E.S. \[[@B55]\]                 107/240     NA            11.11 ± 4.05                  NA                       --           --               IgE-log (IU/ml)                    5.17 ± 1.76                                              NA

  Li, H. \[[@B56]\]                    96/96       96/96         3--12                         18--22                   --           --               --                                 --                                                       --

  Wang, J.Y. \[[@B19]\]                148/301     266/246       7.82 ± 3.81                   8.37 ± 2.45              --           --               IgE-ln (IU/ml)                     5.9848 ± 1.5276                                          4.5201 ± 1.6375

  Dmitrieva-Zdorova, E.V. \[[@B59]\]   119/105     74/98         Mild 32.7 ± 10.5\             36.9 ± 10.1              --           --               IgE level (IU/ml)                  Mild 210 (53--535)\                                      45 (23--89)
                                                                 Moderate/severe 38.3 ± 12.6                                                                                             Moderate/severe 252 (128--645)                           

  Zheng, B.Q. \[[@B51]\]               94/104      50/60         3.5                           3.8                      --           --               --                                 --                                                       --

  Ramphul, K. \[[@B60]\]               --          --            3--12                         18--22                   --           --               --                                 --                                                       --

  Amo, G. \[[@B61]\]                   294/221     265/261       32.2 ± 15.1 (14--79)          28.4 ± 12.1 (18--84)     --           --               IgE level (IU/ml)                  254.1 ± 401.5 (0--4800)                                  NA

  Hua, L. \[[@B62]\]                   497/503     497/503       4.90 (3--12)                  23.32 (18--25)           807          NA               --                                 --                                                       --

  -109C/T                                                                                                                                                                                                                                         

  Hizawa, N. \[[@B13]\]                119/107     102/124       TT 45.8 ± 16.5\               TT 41.6 ± 11.5\          EE 68\       EE 30\           IgE-log (IU/ml)                    TT 2.63 ± 0.56\                                          TT 1.73 ± 0.57\
                                                                 TC 44.3 ± 16.5\               TC 42.8 ± 11.5\          EG 87\       EG 31\                                              TC 2.37 ± 0.56\                                          TC 1.73 ± 0.58\
                                                                 CC 42.8 ± 16.5                CC 39.4 ± 11.5           GG 17        GG 4                                                CC 2.44 ± 0.56                                           CC 1.75 ± 0.57

  Cui, T.P. \[[@B17]\]                 47/59       48/54         40.37 ± 15.09 (18--69)        37.12 ± 12.63 (20--60)   --           --               IgE-log (IU/ml)                    TT 2.649 ± 0.9241\                                       NA
                                                                                                                                                                                         TC 2.296 ± 1.1040\                                       
                                                                                                                                                                                         CC 2.313 ± 0.8052                                        

  Cui, T.P. \[[@B47]\]                 101/115     93/105        19.6 ± 21.9 (3--65)           22.3 ± 23.6 (3--60)      --           --               IgE-log (IU/ml)                    TT 2.441 ± 0.9438\                                       NA
                                                                                                                                                                                         TC 2.315 ± 0.8660\                                       
                                                                                                                                                                                         CC 2.287 ± 1.1150                                        

  Gan, X. \[[@B48]\]                   24/21       22/23         6--65                         8--55                    --           --               IgE level (IU/ml) ≥ 480 (N)        34                                                       8

  Zhao, K.S, \[[@B50]\]                50/76       35/52         1.5--14                       1--12                    TT 10\       TT 1\            IgE-log (IU/ml)                    TT 2.26 ± 0.56\                                          TT 1.54 ± 0.09\
                                                                                                                        TC 55\       TC 3\                                               TC 2.32 ± 0.67\                                          TC 1.52 ± 0.08\
                                                                                                                        CC 39        CC 3                                                CC 2.66 ± 0.37                                           CC 1.52 ± 0.09

  Hizawa, N. \[[@B54]\]                209/165     128/246       45 (16--81)                   32 (18--72)              269          210              IgE-log (IU/ml)                    2.40 ± 0.64                                              1.86 ± 0.64

  Kim, E.S. \[[@B55]\]                 107/240     NA            11.11 ± 4.05                  NA                       --           --               IgE-log (IU/ml)                    5.17 ± 1.76                                              NA

  Li, H. \[[@B56]\]                    96/96       96/96         3--12                         18--22                   --           --               --                                 --                                                       --

  Sharma, S. \[[@B57]\]                123/114     117/104       34.4 ± 12.5                   35.0 ± 10.6              --           --               IgE-log (IU/ml)                    2.85 ± 0.47                                              2.32 ± 0.83

  Tikhonova, V. \[[@B58]\]             26/114      65/71         3--17                         4--17                    --           --               --                                 --                                                       --

  Ramphul, K. \[[@B60]\]               --          --            3--12                         18--22                   --           --               --                                 --                                                       --

  Amo, G. \[[@B61]\]                   294/221     265/261       32.2 ± 15.1 (14--79)          28.4 ± 12.1 (18--84)     --           --               IgE level (IU/ml)                  254.1 ± 401.5 (0--4800)                                  NA

  Hua, L. \[[@B62]\]                   497/503     497/503       4.90 (3--12)                  23.32 (18--25)           807          NA               --                                 --                                                       --
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: NA, not available; RAST, allergy skin prick test result.

Association of RsaI_in2, RsaI_ex7, and I181L polymorphisms in asthma and/or allergic rhinitis risk {#sec3-3}
--------------------------------------------------------------------------------------------------

For these three polymorphisms, three studies that focused on the association of RsaI_in2 polymorphisms and allergic diseases risk involving 274 cases and 217 controls, two studies that focused on the association between RsaI_ex7 polymorphisms and allergic diseases risk involving 177 cases and 130 controls, and two studies that focused on the association of I181L polymorphisms and allergic diseases risk involving 290 cases and 150 controls were pooled into the meta-analysis. No significant association was found for RsaI_in2 and RsaI_ex7 polymorphisms in all genetic models. For I181L polymorphism, significant association with increased allergic diseases risk was also observed in B vs. A (OR = 2.00, 95%CI = 1.35-2.97), AB+BB vs. AA (OR = 4.19, 95%CI = 2.35-7.47) and AB vs. AA (OR = 4.15, 95%CI = 2.33-7.41) genetic models.

Sensitivity analysis and publication bias {#sec3-4}
-----------------------------------------

We omitted each particular study to verify whether our results were influenced by each individual study or not. The pooled ORs were not materially altered, indicating the robustness and stable of the results in this meta-analysis ([Figure 6](#F6){ref-type="fig"}). The Begg's funnel plot and Egger's test were used to evaluate the publication bias ([Table 4](#T4){ref-type="table"}). All the plots were found to be roughly symmetrical, indicating no publication bias presented as shown in [Figure 7](#F7){ref-type="fig"}.

![Sensitivity analysis through the deletion of each study to reflect the individual influence on the calculated ORs in allelic genetic model of E237G polymorphism](bsr-38-bsr20180177-g6){#F6}

![Funnel plot analysis to detect publication bias for allelic genetic model of E237G polymorphism\
The weight of studies is presented by the size of circles.](bsr-38-bsr20180177-g7){#F7}

###### Evaluation of the publication bias of E237G and -109 C/T polymorphisms of the included studies

  Genotype      B vs. A   AB + BB vs. AA   BB vs. AA + AB   BB vs. AA   AB vs. AA
  ------------- --------- ---------------- ---------------- ----------- -----------
  E237G                                                                 
  *P*(Begg's)   0.168     0.797            0.085            0.487       0.907
  *P*(Egger)    0.102     0.358            0.012            0.307       0.333
  -109 C/T                                                              
  *P*(Begg's)   0.656     0.656            0.921            0.235       0.882
  *P*(Egger)    0.894     0.555            0.128            0.411       0.589

Discussion {#sec4}
==========

In the last decade, analysis of SNPs has become the newest approach for detection and localization of the genetic determinants of asthma \[[@B63]\]. Genetic factors are important in defining total serum IgE levels. Linkage analyses have localized a gene or genes that influence atopic phenotype at chromosome 11q13 \[[@B34]\]. In this meta-analysis, we discussed five polymorphisms in FcεRIβ (E237G, -109 C/T, RsaI_in2, RsaI_ex7, and I181L) which were considered to have certain correlation to allergic diseases by pooled results from 29 eligible case--control studies. Only two extensively investigated SNPs (E237G and -109 C/T) were involving large sample of studies included this meta-analysis. Other SNPs (RsaI_in2, RsaI_ex7, and I181L) had limited number of studies, especially for V183L, we failed to collect enough studies and data to comprehensively analyze the risk for allergic diseases.

The results demonstrated that FcεRIβ E237G polymorphism in allelic model acts as significant increased risk for asthma, especially in Asians, which is consistent with previous results \[[@B66],[@B67]\]. The stratification on allergic status and ethnicity did reveal a statistically significant association for E237G and the risk of allergic diseases. With respect to FcεRIβ -109 C/T polymorphism, a significantly association was observed in recessive genetic model, it has been demonstrated that -109 C/T polymorphism may play an important role in pathophysiologic mechanisms and the subgroup analysis by allergic status and ethnicity also showed the increased risk for allergic diseases, which validated the previous speculation \[[@B67]\]. For I181L polymorphism, significant association with increased allergic diseases risk was also observed in three genetic models, given the limited number of studies, more data are required to validate these associations.

Heterogeneity is one of the most important problems when performing the meta-analysis. The results should be interpreted with caution when heterogeneity exists. There was high heterogeneity in this meta-analysis. Considering that differences in allergic status, ethnicity and WHE may affect the results, we conducted subgroup analysis by allergic status, ethnicities and WHE, the heterogeneity was decreased or removed after subgroup analysis; however, there still existed or increased in some groups, perhaps, the source of heterogeneity may be from different ages or other clinical characteristics such as sex and environmental exposures, unfortunately, there were no enough data to extract to analyze.

Although this is not the first meta-analysis focused on the association between FcεRIβ polymorphisms and allergic diseases, there were some strengths of our study: first, most of the genotype distributions in controls were consistent with HWE. Second, the relationship was analyzed by using five kinds of genetic models, and the results were statistically significant. Third, the methodological issues for meta-analysis, such as Egger's test, Begg's funnel plots, and subgroup analysis were performed to ensure the stability of the results. On the other hand, the limitations could not be ignored: first, the interaction of gene--gene and gene--environment should be considered. Second, most of the included studies were conducted in Asian and Caucasian populations, although other ethnicities should be considered. Third, different genotyping methods were used in the respective studies, which might partly influence the result.

Conclusions {#sec5}
===========

In conclusions, it is believed that subjects with FcεRIβ polymorphisms tend to develop allergic diseases, severity of symptoms caused by genetic variation could independently modify predisposition to allergic diseases. A greater understanding of the genetic basis of asthma and allergic rhinitis holds great promise for the identification of novel therapeutic targets. Further multicentric investigations still need to confirm the relationship of these polymorphisms of FcεRIβ and allergic diseases susceptibility.

Author Contribution {#sec6}
===================

H.H.G. and X.H.Z. conceived and designed the study. H.H.G. and P.L. searched the databases and extracted the data. T.P. and H.B.L. analyzed the data. H.H.G., S.H., and S.L. wrote the draft of the paper. X.H.Z. and W.D.Z. reviewed and revised the manuscript. All the authors approved the final manuscript.

Funding {#sec7}
=======

The authors declare that there are no sources of funding to be acknowledged.

Competing Interests {#sec8}
===================

The authors declare that there are no competing interests associated with the manuscript.

AR

:   allergic rhinitis

CI

:   confidence interval

HWE

:   hardy--weinberg equilibrium

NOS

:   newcastle--ottawa scale

OR

:   odd ratio

SNP

:   single nucleotide polymorphism
